Addex Therapeutics Schedules Annual General Meeting for 2024

Addex Therapeutics Ltd ADXN, a biopharmaceutical company focused on the development of small molecule therapeutics for central nervous system (CNS) disorders, has officially announced the scheduling of its Annual General Meeting (AGM) for 2024. In compliance with Art. 53 LR, this notice serves as an ad hoc announcement for shareholders and the investment community at large.

Agenda for the 2024 AGM

The agenda for the upcoming AGM is to address the key accomplishments of the previous year, outline the strategic priorities for the future, and engage with shareholders on important corporate matters. Addex Therapeutics, with its headquarters in Geneva, Switzerland, is committed to transparency and accountability in its operations, ensuring that stakeholders are well-informed and involved in the company's progression.

Financial and Operational Highlights

In the lead-up to the AGM, Addex will be providing updates on its financial standings, pipeline progress, and any significant corporate developments that have taken place over the fiscal year. The meeting will also be an opportunity for shareholders to ask questions and provide feedback directly to the company's leadership team. The development-stage company's continuous efforts in advancing its portfolio of CNS treatments is a testament to its dedication to addressing unmet medical needs.

Addex, AGM, Announcement